ReviewDescription of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome☆
Introduction
Neonatal lupus syndrome caused by passive transplacental passage of maternal anti-SSA and/or anti-SSB antibodies is a rare disorder mainly represented by cardiac neonatal lupus and skin rash. Cardiac manifestations include congenital heart block (CHB), endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM) [1], [2], [3], [4], [5], [6], [7], [8], [9]. CHB is defined by atrio-ventricular block occurring in utero or in the neonatal period (< 28 days of life) [9]. Its prevalence is less than 1% in anti-SSA-positive women [9], [10] and the recurrence rate is estimated at 19% [11]. Its treatment is currently very controversial. Fluorinated steroids, that do cross the placenta, have been used for some decades, including in France but their efficacy has been recently challenged by 2 different groups [12], [13].
International efforts have attempted to improve the understanding and management of this condition, with major contributions from different groups [8], [12], [14], [15], [16], [17], [18], [19]. However, registries are needed to improve our knowledge and the management of CHB. Buyon first established the US registry of neonatal lupus and recently reported 312 cases of second- and third-degree CHB [13]. A European and Brazilian study, which did not include French cases, reported 175 CHB cases, but only 131 with anti-SSA or anti-SSB antibodies [12]. To our knowledge, no data on other large registries are available.
Here, we give a descriptive analysis of 214 cases of high-degree CHB associated with maternal anti-SSA and/or -SSB antibodies that are included in the neonatal lupus French registry.
Section snippets
Patients
This registry, established in 2000 with Institutional Review Board approval, includes fetuses or children with neonatal lupus born to mothers with anti-SSA and/or anti-SSB antibodies. Inclusion criteria were (1) enrolment in the registry by September 2014, (2) maternal anti-SSA and/or anti-SSB antibodies, (3) confirmation of second- or third-degree CHB documented by electrocardiography and/or fetal echocardiography, and (4) diagnosis of CHB in utero or in the neonatal period. In cases of CHB
Patient demographics
By September 2014, the registry included 254 cases of cardiac neonatal lupus: 214 cases of second- or third-degree CHB, 19 cases of EFE, 13 heart blocks diagnosed after the neonatal period and 8 other miscellaneous manifestations. To have homogeneous data and according to our inclusion and exclusion criteria, we analyzed data of the 214 advanced CHB cases.
These 214 fetuses or children were born to 195 mothers between 1976 and 2014 (142 pregnancies between 2000 and 2014); 194 mothers (99.5%)
Discussion
We report for the first time, data from the French national registry of neonatal lupus syndrome, with 214 cases of high-degree CHB associated with anti-SSA and/or anti-SSB antibodies. By comparison, the two other large studies from the US registry [13] and from a European/Brazilian registry [12] recently included 278 and 131 of such cases, respectively. Maternal disease data were relatively similar between the three registries, most of the mothers having no CTD. The respective number of cases
Conclusion
We confirmed some of the previous results from other large registries. Unfortunately, our data do not support the routine use of in utero fluorinated steroids for the treatment of cardiac neonatal lupus syndrome.
Funding sources
None.
Disclosures
None.
Take-home messages
- •
Feto-neonatal mortality of CHB was 15.7%.
- •
Factors associated with feto-neonatal deaths were hydrops and prematurity.
- •
During a median follow-up period of 7 years [birth to 36 years] of 148 children born alive, 79% had a pacemaker, 19% had DCM, and 12% died.
- •
Factors associated with child death were in utero DCM, postnatal DCM and pacemaker implantation.
- •
We found no evidence that the use of fluorinated steroids was associated with improved survival or with regression of 2nd degree CHB.
Acknowledgments
We acknowledge the doctors participating to the “Neonatal Lupus Group”, the “Société Nationale Française de Médecine Interne” and the families for their kind collaboration.
This study is dedicated to recently deceased Professor Olivier Meyer.
References (25)
- et al.
Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela
J Am Coll Cardiol
(2001) - et al.
Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block
J Am Coll Cardiol
(2002) - et al.
Letter to the Editor in response to the article “Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials.” by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45
Autoimmun Rev
(2014) - et al.
Neonatal lupus syndrome: literature review
Rev Med Interne
(2015) - et al.
Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status
J Am Coll Cardiol
(2006) - et al.
Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses
J Am Coll Cardiol
(2011) - et al.
Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years
J Am Coll Cardiol
(2002) - et al.
Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials
Autoimmun Rev
(2013) - et al.
Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options
Arthritis Res Ther
(2005) - et al.
A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal anti-SSA/Ro and anti-SSB/La antibodies
J Rheumatol
(2011)
Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis
Circulation
The clinical spectrum of autoimmune congenital heart block
Nat Rev Rheumatol
Cited by (114)
Knowledge is power: regarding SMFM Consult Series #64: Systemic lupus erythematosus in pregnancy
2023, American Journal of Obstetrics and GynecologyPacemaker Management and In-Hospital Outcomes in Neonatal Congenital Atrioventricular Block
2023, JACC: Clinical ElectrophysiologyCongenital Heart Block
2023, Cardiology ClinicsDevelopmental and Inherited Liver Disease
2023, MacSween's Pathology of the Liver, Eighth EditionWhen to consider primary Sjögren's syndrome?
2022, Revue du Rhumatisme MonographiesComplete Congenital Atrioventricular Block Found by Ultrasound in Pregnancy
2022, Annals of Emergency Medicine